Haldol (haloperidol) is not an atypical antipsychotic. It is a typical, or first-generation, antipsychotic, and one of the oldest still in widespread use. The FDA first approved it in 1967, decades before the atypical antipsychotics like olanzapine, quetiapine, and risperidone came to market in the 1990s. Understanding which category Haldol falls into matters because the two classes differ in how they work, what side effects they cause, and what tradeoffs you face during treatment.
Typical vs. Atypical: What the Difference Means
The terms “typical” and “atypical” describe two generations of antipsychotic medications. Typical antipsychotics, including haloperidol, primarily work by blocking one type of chemical signaling pathway in the brain involved in psychosis. Atypical antipsychotics block that same pathway but also affect a second signaling system related to mood and cognition. That broader mechanism is what gave atypical drugs their name: they acted in an atypical way compared to the older medications.
In practice, this distinction shapes the side effect profile more than the effectiveness. Both generations can manage psychotic symptoms. But the types of problems they cause tend to differ, sometimes significantly.
What Haldol Is Used For
Haloperidol is prescribed for psychotic disorders, including schizophrenia and similar conditions that cause disordered thinking and perception. It is also used to control both motor and vocal tics in people with Tourette’s disorder, and to treat severe confusion or delirium caused by serious illness. In hospital settings, it remains one of the most commonly used antipsychotics for acute agitation because it works quickly and can be given by injection.
A long-acting injectable form, Haldol Decanoate, is given once every four weeks by deep intramuscular injection. After the shot, levels of the drug in the blood rise gradually, peaking around six days later, then slowly decline over about three weeks. This formulation is useful for people who have difficulty taking daily oral medication consistently.
Movement-Related Side Effects
The most important practical difference between Haldol and atypical antipsychotics is the risk of movement problems, clinically known as extrapyramidal symptoms. These include muscle stiffness and tremor (resembling Parkinson’s disease), involuntary muscle contractions, and a distressing inner restlessness called akathisia that makes it nearly impossible to sit still.
In the EUFEST trial, which followed people through their first episode of schizophrenia, haloperidol caused noticeably more of these movement problems than the newer drugs tested alongside it. After one month of treatment, the increase in Parkinson’s-like symptoms was highest in the haloperidol group, jumping by 13 percentage points. Nearly a quarter of patients on haloperidol needed an additional medication just to counteract these movement effects, compared to much lower rates in the groups taking atypical antipsychotics.
After a full year of treatment, movement side effects had generally decreased across all groups, but the haloperidol group still had the highest rate of Parkinson’s-like symptoms at about 9%, and the highest use of corrective medications at roughly 11%. It’s worth noting that in the CATIE trial, which studied people with chronic schizophrenia, the differences between older and newer antipsychotics were less dramatic, suggesting the gap may narrow over time or vary by patient population.
Tardive Dyskinesia Risk
A more serious long-term concern with haloperidol is tardive dyskinesia, a condition involving involuntary, repetitive movements, often of the face, tongue, and jaw. Unlike other movement side effects that may improve when the dose is lowered, tardive dyskinesia can be permanent.
Studies have found that haloperidol carries an annual incidence of tardive dyskinesia between roughly 4% and 7.4% in adults. That risk accumulates over time, so the longer someone takes the drug, the greater the chance of developing it. For young adults on any typical antipsychotic, the annual cumulative rate runs about 4% to 5%. Atypical antipsychotics carry a lower risk, which is one of the main reasons they became the preferred first-line treatment for most people with schizophrenia.
Metabolic Effects: Where Haldol Has an Advantage
One area where haloperidol actually compares favorably to many atypical antipsychotics is weight gain and metabolic health. A large network meta-analysis published in The Lancet Psychiatry found that haloperidol caused virtually no weight change compared to placebo, with an average difference of just negative 0.23 kilograms. For context, clozapine averaged 3.01 kg of weight gain and olanzapine produced the largest increases in BMI.
Haloperidol also had minimal effects on cholesterol, blood sugar, and triglycerides. This is a meaningful consideration because several atypical antipsychotics, particularly olanzapine and clozapine, substantially raise the risk of weight gain, diabetes, and high cholesterol. So while the atypical drugs are often gentler on the movement system, some of them create serious metabolic problems that haloperidol largely avoids. Not all atypicals are equal in this regard: aripiprazole, lurasidone, and ziprasidone have relatively clean metabolic profiles as well.
Safety Concerns in Older Adults
Haldol carries an FDA black box warning, the most serious type of safety alert, regarding use in elderly patients with dementia-related psychosis. Antipsychotic drugs as a class increase the risk of death in this population. Analyses of 17 placebo-controlled trials found that the death rate in drug-treated patients was about 4.5% over a typical 10-week period, compared to 2.6% in those receiving placebo. That translates to roughly 1.6 to 1.7 times the risk. Most deaths were cardiovascular (heart failure, sudden death) or infectious (pneumonia) in nature.
This warning applies to both typical and atypical antipsychotics. Haldol is not approved for treating dementia-related psychosis.
Why Haldol Is Still Used
Given the movement risks, you might wonder why haloperidol hasn’t been entirely replaced. Several factors keep it in use. It is highly effective for acute psychosis and agitation, particularly in emergency and hospital settings. Its injectable forms, both short-acting and the monthly long-acting version, provide options that not all newer drugs offer. It causes less sedation than some atypicals, carries minimal metabolic risk, and decades of clinical experience make its effects highly predictable. For certain patients, especially those who have struggled with weight gain or metabolic problems on atypical antipsychotics, haloperidol may represent a reasonable alternative when the movement risks are carefully monitored.
The bottom line is that Haldol belongs firmly in the typical antipsychotic category. It works well for the conditions it treats, but it comes with a different set of tradeoffs than the newer atypical drugs. The choice between the two classes depends on which risks matter most for a given person’s health and circumstances.